Survodutide

CAT:
804-HY-P4146-01
Size:
1 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Survodutide - image 1

Survodutide

  • Description:

    Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake[1].
  • Product Name Alternative:

    BI 456906
  • UNSPSC:

    12352209
  • Target:

    GCGR; GLP Receptor
  • Type:

    Peptides
  • Related Pathways:

    GPCR/G Protein
  • Applications:

    Metabolism-protein/nucleotide metabolism
  • Field of Research:

    Metabolic Disease
  • Assay Protocol:

    https://www.medchemexpress.com/survodutide.html
  • Purity:

    99.92
  • Solubility:

    DMSO : 100 mg/mL (ultrasonic)
  • Smiles:

    O=C(NC1(C(NC(CCC(N)=O)C(NCC(NC(C(O)C)C(NC(CC2=CC=CC=C2)C(NC(C(O)C)C(NC(CO)C(NC(CC(O)=O)C(NC(CC3=CC=C(C=C3)O)C(NC(CO)C(NC(CCCCN)C(NC(CC4=CC=C(C=C4)O)C(NC(CC(C)C)C(NC(CC(O)=O)C(NC(CCC(O)=O)C(NC(CCCNC(N)=N)C(NC(C)C(NC(C)C(NC(CCCCN)C(NC(CC(O)=O)C(NC(CC5=CC=CC=C5)C(NC(C(C)CC)C(NC(CCCCNC(CNC(CNC(C(NC(CNC(C(NC(CNC(CCC(C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)CO)=O)=O)CO)=O)=O)=O)C(NC(CC6=CNC7=CC=CC=C67)C(NC(CC(C)C)C(NC(CCC(O)=O)C(NC(CO)C(NC(C)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCC1)C(CC8=CNC=N8)N
  • Molecular Formula:

    C192H289N47O61
  • Molecular Weight:

    4231.63
  • References & Citations:

    [1]Tina Zimmermann, et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab. 2022 Dec:66:101633.
  • Shipping Conditions:

    Blue Ice
  • Storage Conditions:

    -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
  • Scientific Category:

    Peptides
  • Clinical Information:

    Phase 3
  • CAS Number:

    [2805997-46-8]